Public disclosure of inside information according to article 17 MAR
Leverkusen, Germany (pta018/20.02.2024/13:45) - Biofrontera AG today entered into an agreement with Biofrontera Inc. to modify the business relationship between the two companies. Biofrontera AG will focus on capitalizing its existing projects and know-how, while research and development will no longer be a core part of its activities. This revised strategy and the amended agreement with Biofrontera AG's largest customer, Biofrontera Inc., will have a significant impact on the structure of revenues and costs, both of which will be reduced. Biofrontera AG will provide new guidance for 2024 in due course.
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate